Literature DB >> 35131041

Equity in access to long-acting injectables in the USA.

J Carlo Hojilla1, Monica Gandhi2, Derek D Satre3, Mallory O Johnson4, Parya Saberi4.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35131041      PMCID： PMC8936932          DOI： 10.1016/S2352-3018(22)00031-5

Source DB:  PubMed          Journal:  Lancet HIV        ISSN： 2352-3018            Impact factor:   12.767


× No keyword cloud information.
  8 in total

Review 1.  Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection.

Authors:  Ronald D'Amico; David A Margolis
Journal:  Curr Opin HIV AIDS       Date:  2020-01       Impact factor: 4.283

2.  Self-injection of monthly combined hormonal contraceptive.

Authors:  Nancy L Stanwood; Kara Eastwood; Alison Carletta
Journal:  Contraception       Date:  2005-11-14       Impact factor: 3.375

3.  Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem.

Authors:  L Bahamondes; N M Marchi; H M Nakagava; M L de Melo; M de L Cristofoletti; E Pellini; R H Scozzafave; C Petta
Journal:  Contraception       Date:  1997-11       Impact factor: 3.375

4.  Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.

Authors:  Chloe Orkin; Shinichi Oka; Patrick Philibert; Cynthia Brinson; Ayesha Bassa; Denis Gusev; Olaf Degen; Juan González García; Enrique Bernal Morell; Darrell H S Tan; Ronald D'Amico; David Dorey; Sandy Griffith; Shanker Thiagarajah; Marty St Clair; Rodica Van Solingen-Ristea; Herta Crauwels; Susan L Ford; Parul Patel; Vasiliki Chounta; Simon Vanveggel; Amy Cutrell; Veerle Van Eygen; Kati Vandermeulen; David A Margolis; Kimberly Y Smith; William R Spreen
Journal:  Lancet HIV       Date:  2021-04       Impact factor: 12.767

5.  Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV.

Authors:  Jane M Simoni; Kristin Beima-Sofie; Zahra H Mohamed; Joan Christodoulou; Kenneth Tapia; Susan M Graham; Rodney Ho; Ann C Collier
Journal:  AIDS Patient Care STDS       Date:  2019-03       Impact factor: 5.944

6.  Effects of community-based antiretroviral therapy initiation models on HIV treatment outcomes: A systematic review and meta-analysis.

Authors:  Ingrid Eshun-Wilson; Ajibola A Awotiwon; Ashley Germann; Sophia A Amankwaa; Nathan Ford; Sheree Schwartz; Stefan Baral; Elvin H Geng
Journal:  PLoS Med       Date:  2021-05-28       Impact factor: 11.069

7.  Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.

Authors:  Susan Swindells; Thomas Lutz; Lelanie Van Zyl; Norma Porteiro; Matthias Stoll; Essack Mitha; Alyssa Shon; Paul Benn; Jenny O Huang; Conn M Harrington; Kai Hove; Susan L Ford; Christine L Talarico; Vasiliki Chounta; Herta Crauwels; Rodica Van Solingen-Ristea; Simon Vanveggel; David A Margolis; Kimberly Y Smith; Kati Vandermeulen; William R Spreen
Journal:  AIDS       Date:  2022-02-01       Impact factor: 4.632

Review 8.  The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.

Authors:  John T Kanazawa; Parya Saberi; John A Sauceda; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2020-12-07       Impact factor: 2.205
  8 in total
  1 in total

1.  Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South.

Authors:  Lauren F Collins; Della Corbin-Johnson; Meron Asrat; Zoey P Morton; Kaylin Dance; Alton Condra; Kimberly Jenkins; Marie Todd-Turner; Jeri Sumitani; Bradley L Smith; Wendy S Armstrong; Jonathan A Colasanti
Journal:  Open Forum Infect Dis       Date:  2022-09-02       Impact factor: 4.423
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.